Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

5.250 -0.250 (-4.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Taysha Gene Therapies, Inc. (TSHA) Q3 2021 Earnings Call Transcript ↗
TSHA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
From Taysha Gene Therapies
Via Business Wire
News headline image
Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Analyst Ratings For Taysha Gene Therapies ↗
Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst rat... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
Taysha Gene Therapies Announces Publication of Positive Proof-of-Concept Preclinical Data for an AAV-mediated UBE3A Gene Replacement Approach Demonstrating Therapeutic Potential for The Treatment of Angelman Syndrome in the Journal JCI Insight
From Taysha Gene Therapies
Via Business Wire
News headline image
Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth Association Centers of Excellence
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-106 for the Treatment of Angelman Syndrome
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Next-Generation Construct for CLN7 and a Grant Award to Batten Hope
From Taysha Gene Therapies
Via Business Wire
News headline image
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies to Participate in Upcoming October Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Receives Orphan Drug Designation from the European Commission for TSHA-102 for the Treatment of Rett Syndrome
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies Announces Publication of Positive Preclinical Data for TSHA-104 Demonstrating Therapeutic Potential in SURF1-associated Leigh Syndrome in Journal Molecular Therapy: Methods & Clinical Development
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-102 for the Treatment of Rett Syndrome
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies to Participate in Upcoming September Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha's Rare Epilepsy Gene Therapy Receives European Orphan Drug Tag ↗
The European Commission has granted Orphan Drug designation to Taysha Gene Therapies Inc's (NASDAQ: TSHA) TSHA-105, AAV9-based gene therapy for SLC13A5-... 
Via Benzinga
News headline image
Taysha Gene Therapies Receives Orphan Drug Designation for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency From the European Commission
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock increased by 25.72% to $2.59 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Tuesday morning, 282 companies set new 52-week lows. Key Facts: Alibaba Group Holding (NYSE:BABA) was the biggest company by market cap to set a new 52-week low.... 
Via Benzinga
News headline image
Taysha Gene Therapies to Host Key Opinion Leader Webinar on TSHA-118 for the Treatment of CLN1 Disease
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies, Inc. (TSHA) Q2 2021 Earnings Call Transcript ↗
TSHA earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Taysha Gene Secures $100M In Debt Financing For Support Pipeline Development ↗
Taysha Gene Therapies Inc (NASDAQ: TSHA) has entered into a loan and security agreement with Silicon Valley Bank (SVB), providing up to $100 million of... 
Via Benzinga
News headline image
Taysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
From Taysha Gene Therapies
Via Business Wire
News headline image
Taysha Gene Therapies Secures up to $100 Million Non-Dilutive Term Loan Financing
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies to Release Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 16
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Taysha Gene Therapies to Participate in Upcoming August Investor Healthcare Conferences
From Taysha Gene Therapies, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 16, 2021 ↗
Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter. • Data Storage (NASDAQ:DTST) is expected to... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.